Medications for Muscular Dystrophy Duchenne

6 results

  • amondys 45

    (casimersen)
    Sarepta Therapeutics, Inc.
    AMONDYS 45 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene suitable for exon 45 skipping. Approval is based on increased dystrophin production in skeletal muscle, with continued approval subject to further confirmation of clinical benefit.

  • deflazacort

    (Deflazacort)
    Sun Pharmaceutical Industries Limited
    Deflazacort tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 5 years and older. Additional pediatric use information exists but is not included on the label due to marketing exclusivity rights.

  • emflaza

    (deflazacort)
    PTC Therapeutics, Inc.
    EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.

  • exondys 51

    (eteplirsen)
    Sarepta Therapeutics, Inc.
    EXONDYS 51 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene suitable for exon 51 skipping. Its approval is based on observed increases in dystrophin in skeletal muscle, pending further verification of clinical benefit in ongoing trials.

  • viltepso

    (viltolarsen)
    NS Pharma, Inc.
    VILTEPSO is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation suitable for exon 53 skipping. Approval is based on increased dystrophin production in skeletal muscle, with continued approval dependent on further verification of clinical benefits.

  • vyondys 53

    (golodirsen)
    Sarepta Therapeutics, Inc.
    VYONDYS 53 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation suitable for exon 53 skipping. Approval is based on increased dystrophin production in skeletal muscle, with continued approval dependent on clinical benefit verification in further trials.